Prestige Consumer Healthcare Past Earnings Performance
Past criteria checks 3/6
Prestige Consumer Healthcare's earnings have been declining at an average annual rate of -2.3%, while the Pharmaceuticals industry saw earnings growing at 1.8% annually. Revenues have been growing at an average rate of 4.1% per year. Prestige Consumer Healthcare's return on equity is 12%, and it has net margins of 19.1%.
Key information
-2.3%
Earnings growth rate
-2.1%
EPS growth rate
| Pharmaceuticals Industry Growth | 6.0% |
| Revenue growth rate | 4.1% |
| Return on equity | 12.0% |
| Net Margin | 19.1% |
| Last Earnings Update | 31 Dec 2024 |
Recent past performance updates
Recent updates
Results: Prestige Consumer Healthcare Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates
Feb 09
Here's Why Prestige Consumer Healthcare (NYSE:PBH) Can Manage Its Debt Responsibly
Feb 07Pinning Down Prestige Consumer Healthcare Inc.'s (NYSE:PBH) P/S Is Difficult Right Now
Jan 16Prestige Consumer Healthcare Inc. (NYSE:PBH) Shares Could Be 45% Below Their Intrinsic Value Estimate
Dec 04We Think Prestige Consumer Healthcare (NYSE:PBH) Can Stay On Top Of Its Debt
Nov 03Prestige Consumer Healthcare Inc.'s (NYSE:PBH) Popularity With Investors Is Under Threat From Overpricing
Sep 10Prestige Consumer Healthcare (NYSE:PBH) Seems To Use Debt Quite Sensibly
Jul 16Revenues Not Telling The Story For Prestige Consumer Healthcare Inc. (NYSE:PBH)
May 22Here's Why Prestige Consumer Healthcare (NYSE:PBH) Can Manage Its Debt Responsibly
Mar 26An Intrinsic Calculation For Prestige Consumer Healthcare Inc. (NYSE:PBH) Suggests It's 50% Undervalued
Mar 05Prestige Consumer Healthcare Inc. (NYSE:PBH) Just Released Its Third-Quarter Results And Analysts Are Updating Their Estimates
Feb 11Prestige Consumer Healthcare Inc.'s (NYSE:PBH) Shares May Have Run Too Fast Too Soon
Feb 05Here's Why Prestige Consumer Healthcare (NYSE:PBH) Can Manage Its Debt Responsibly
Dec 14Prestige Consumer Healthcare (NYSE:PBH) Seems To Use Debt Quite Sensibly
Sep 10Prestige Consumer Healthcare: Unproductive Buyback And Excessive Valuation
Aug 15Is Prestige Consumer Healthcare (NYSE:PBH) Using Too Much Debt?
Jun 12An Intrinsic Calculation For Prestige Consumer Healthcare Inc. (NYSE:PBH) Suggests It's 43% Undervalued
May 20Here's Why Prestige Consumer Healthcare (NYSE:PBH) Has Caught The Eye Of Investors
Mar 17Here's Why Prestige Consumer Healthcare (NYSE:PBH) Can Manage Its Debt Responsibly
Mar 02Prestige Consumer Healthcare Inc.'s (NYSE:PBH) Intrinsic Value Is Potentially 75% Above Its Share Price
Feb 08Prestige Consumer Healthcare reports Q3 earnings beat; updates FY23 guidance
Feb 02Prestige Consumer Healthcare: Taking My Winnings Off The Table
Jan 19Here's Why Prestige Consumer Healthcare (NYSE:PBH) Can Manage Its Debt Responsibly
Nov 23Prestige Consumer Healthcare GAAP EPS of $1.02 beats by $0.02, revenue of $289.3M beats by $6.07M
Nov 03Holding Prestige Consumer Healthcare
Aug 31If EPS Growth Is Important To You, Prestige Consumer Healthcare (NYSE:PBH) Presents An Opportunity
Aug 26We Think Prestige Consumer Healthcare (NYSE:PBH) Can Stay On Top Of Its Debt
Aug 05Prestige Consumer Healthcare GAAP EPS of $1.09 beats by $0.05, revenue of $277.1M beats by $8.18M
Aug 04Should You Be Adding Prestige Consumer Healthcare (NYSE:PBH) To Your Watchlist Today?
May 27Is Prestige Consumer Healthcare (NYSE:PBH) A Risky Investment?
May 05Does Prestige Consumer Healthcare (NYSE:PBH) Deserve A Spot On Your Watchlist?
Feb 22Is Prestige Consumer Healthcare (NYSE:PBH) A Risky Investment?
Feb 03Revenue & Expenses Breakdown
How Prestige Consumer Healthcare makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 24 | 1,118 | 214 | 264 | 0 |
| 30 Sep 24 | 1,111 | 206 | 265 | 0 |
| 30 Jun 24 | 1,113 | 205 | 264 | 0 |
| 31 Mar 24 | 1,125 | 209 | 259 | 0 |
| 31 Dec 23 | 1,134 | -81 | 254 | 0 |
| 30 Sep 23 | 1,127 | -82 | 246 | 0 |
| 30 Jun 23 | 1,130 | -84 | 250 | 0 |
| 31 Mar 23 | 1,128 | -82 | 252 | 0 |
| 31 Dec 22 | 1,109 | 210 | 252 | 0 |
| 30 Sep 22 | 1,108 | 209 | 262 | 0 |
| 30 Jun 22 | 1,095 | 203 | 264 | 0 |
| 31 Mar 22 | 1,087 | 205 | 260 | 0 |
| 31 Dec 21 | 1,058 | 189 | 261 | 0 |
| 30 Sep 21 | 1,022 | 179 | 255 | 0 |
| 30 Jun 21 | 983 | 179 | 240 | 0 |
| 31 Mar 21 | 943 | 165 | 224 | 0 |
| 31 Dec 20 | 957 | 166 | 230 | 0 |
| 30 Sep 20 | 960 | 163 | 225 | 0 |
| 30 Jun 20 | 960 | 152 | 227 | 0 |
| 31 Mar 20 | 963 | 142 | 236 | 0 |
| 31 Dec 19 | 953 | -34 | 224 | 0 |
| 30 Sep 19 | 953 | -34 | 224 | 0 |
| 30 Jun 19 | 954 | -36 | 224 | 0 |
| 31 Mar 19 | 976 | -36 | 233 | 0 |
| 31 Dec 18 | 991 | 64 | 231 | 0 |
| 30 Sep 18 | 1,020 | 340 | 233 | 0 |
| 30 Jun 18 | 1,039 | 340 | 233 | 0 |
| 31 Mar 18 | 1,041 | 340 | 229 | 0 |
| 31 Dec 17 | 1,026 | 390 | 227 | 0 |
| 30 Sep 17 | 972 | 107 | 223 | 0 |
| 30 Jun 17 | 929 | 109 | 210 | 0 |
| 31 Mar 17 | 882 | 69 | 199 | 0 |
| 31 Dec 16 | 849 | 72 | 190 | 0 |
| 30 Sep 16 | 833 | 69 | 186 | 0 |
| 30 Jun 16 | 824 | 68 | 183 | 0 |
| 31 Mar 16 | 806 | 100 | 179 | 0 |
| 31 Dec 15 | 788 | 110 | 166 | 0 |
| 30 Sep 15 | 786 | 103 | 167 | 0 |
| 30 Jun 15 | 761 | 88 | 180 | 0 |
| 31 Mar 15 | 715 | 78 | 167 | 0 |
| 31 Dec 14 | 668 | 70 | 167 | 0 |
| 30 Sep 14 | 615 | 52 | 154 | 0 |
| 30 Jun 14 | 601 | 69 | 134 | 0 |
| 31 Mar 14 | 597 | 73 | 132 | 0 |
Quality Earnings: PBH has high quality earnings.
Growing Profit Margin: PBH became profitable in the past.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: PBH has become profitable over the past 5 years, growing earnings by -2.3% per year.
Accelerating Growth: PBH has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: PBH has become profitable in the last year, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (42.6%).
Return on Equity
High ROE: PBH's Return on Equity (12%) is considered low.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/16 12:30 |
| End of Day Share Price | 2025/02/14 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Prestige Consumer Healthcare Inc. is covered by 16 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Olivia Tong Cheang | BofA Global Research |
| Linda Bolton-Weiser | B. Riley Securities, Inc. |
| Susan Anderson | Canaccord Genuity |